Validation of Ferromagnetic Tracer in Melanoma Sentinel Node

Sociedad Española de Oncología Quirúrgica186 enrolled

Overview

This study has been designed to validate a non-radioactive method to identify the sentinel lymph node using a superparamagnetic iron-oxide (SPIO) tracer respect to the traditional isotopic method. Both methods are used in every included patient and each patient is its own control.

* Injection of the isotopic tracer in standard form and in the usual preoperative period (hours-day). * Identical injection in three-four punctures of 2 mL of Sienna+ ® and local massage of 5-10 minutes. * Optional: colorant injection in standard form. Local massage of 5-10 minutes. * After 20 minutes: transcutaneous measurement with SentiMag® * Valuing territories (lymphoscintigraphy information?) * Surgical identification measures: 1. st with SentiMag® 2. nd with gamma detection probe * Ex vivo check and HRD record

Study Type

OBSERVATIONAL

Enrollment

186

Conditions

Melanoma Stage Sentinel Lymph Node

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients (\>18 years of age), * with diagnosis of cutaneous melanoma and * in which SLNB is indicated as a staging method, and * with cN0 result after clinical-echographic-cytohistological evaluation. Exclusion Criteria: * Previous treatment with systemic therapy. * Recent previous surgery (\<3 months) in the area susceptible of lymphatic drainage from the melanoma. * Intolerance or hypersensitivity to iron or dextran compounds. * Impossibility of use of radioisotope. * Existence of pathology related to elevation of organic iron (hemosiderosis, hemochromatosis, iron deficiency anemia of metabolic or circulatory origin). * Implantation of pacemakers or partially or totally metallic thoracic implants. * Treatment with iron chelators (deferasirox, deferoxamine, ...).

Locations (1)

Hospital Clínico Universitario "Virgen de la Arrixaca"

Murcia, Spain

RECRUITING

Outcomes

Primary Outcomes

SN detection

Detection of potential sentinel nodes using both methods (isotopic and ferromagnetic tracers). Máximum register of isotopic and ferromagnetic measurement will be the main criteria.

Time frame: During surgery

Secondary Outcomes

SN agreement

Agreement in isotopic and ferromagnetic sentinel node identification. Measurement criteria will be coincidence in the same node (or nodes).

Time frame: During surgery

Central Contacts

Antonio Piñero Madrona, MD PhD

CONTACT

pineromadrona@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.